Effect of Infliximab in Hepatitis-C Genotype 1 Naïve Patients With High TNF-Alpha on the Efficacy of Pegylated Interferon Alfa-2b/Ribavirin Therapy.
Phase of Trial: Phase III
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Infliximab (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 11 Nov 2012 Primary endpoint 'Sustained-virological-response' has not been met.
- 28 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History